Skip to main content

Ozanimod News

FDA Approves Bristol Myers Squibb’s Zeposia (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

PRINCETON, N.J.--(BUSINESS WIRE) May 27, 2021 – Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) 0.92 mg for the treatment...

FDA Approves Zeposia (ozanimod) for Relapsing Forms of Multiple Sclerosis

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) 0.92 mg for the treatment of...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Ulcerative Colitis, Multiple Sclerosis

Ozanimod patient information at Drugs.com